Corbus Pharmaceuticals Q4 net loss widens on higher clinical development costs

Corbus Pharmaceuticals Holdings

09/03/2026 11:40

Overview

Clinical stage pharma's Q4 net loss widened to $20.6 mln

Operating expenses for Q4 rose to $22 mln, driven by clinical development costs

Outlook

Corbus completed $75 mln public offering, extending cash runway into 2028

Result Drivers

HIGHER OPERATING EXPENSES: Operating expenses increased by $9.4 million to approximately $22.0 million,  increase was primarily attributable to an increase in clinical development expenses.

Company press release: ID:nGNXtxXss

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 Net Income
-$20.56 mln
Q4 Basic EPS
-$1.25
Q4 Operating Expenses
$21.97 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 10 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Corbus Pharmaceuticals Holdings Inc is $39.00, about 386.9% above its March 6 closing price of $8.01

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)